OPKNasdaqPharmaceutical PreparationsFiscal year ends December 31
OPKO HEALTH, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q/A on Aug 28, 2026
$1.61+0.08 (+5.23%)
Close on Oct 19, 2026
- Market cap
- $1.22B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$0.09 (+5.92%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
OPKO HEALTH, INC. saw revenue fall 11.5% to $587.90M over the twelve months to Jun 30, 2026. Free cash flow was -$134.02M.
Revenue
$587.90M
-11.5% vs. a year earlier
Operating income
-$48.25M
TTM Q2 2026
Free cash flow
-$134.02M
TTM Q2 2026
EPS, diluted
-$0.09
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $1.22B
- P/E ratio
- –
- Price to sales
- 2.07
- Price to book
- 1.03
- Dividend yield
- –
- Free cash flow yield
- -11.02%
Fundamentals
- Revenue
- $587.90M
- Net income
- -$72.89M
- EPS, diluted
- -$0.09
- Free cash flow
- -$134.02M
- Book value per share
- $1.57
- Diluted shares
- 755M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$587.90M-11.5% YoY
Gross profit
$239.69M+10.6% YoY
Operating income
-$48.25M
Net income
-$72.89M
EPS, diluted
-$0.09
Free cash flow
-$134.02M
Reported periodTrailing twelve months